Sustained Release Oral Formulation for Treatment of Parkinson's Disease

Summary

Achieving sustained blood levels of carbidopa/levodopa has been a challenge in the treatment of PD and although levodopa remains the most commonly used drug, motor fluctuations remain a major disability especially in advanced Parkinson's disease. The aim of this study is to determine the efficacy of a novel oral carbidopa-levodopa formulation in achieving a sustained blood level of levodopa and carbidopa in normal volunteers.

Eligibility

Age range

18–65 years

Sex

All

Healthy volunteers

Yes

Interventions

• Drug
  levodopa/carbidopa oral formulation A

  Outer sachet 100mg CD/100mg LD and inner sachet 0mg CD /300mg LD

• Drug
  levodopa/carbidopa oral formulation B

  Outer sachet 100mg CD/0mg LD and inner sachet 0mg CD /400mg LD

Location